Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice
暂无分享,去创建一个
D. Fukumura | Meenal Datta | S. Roberge | M. Duquette | Jun Ren | Zohreh Amoozgar | Rakesh K Jain | Xinyue Dong | Somin Lee
[1] C. June,et al. Next-Generation CAR T-cell Therapies. , 2022, Cancer discovery.
[2] A. Griffioen,et al. Directing CAR T cells towards the tumor vasculature for the treatment of solid tumors. , 2022, Biochimica et biophysica acta. Reviews on cancer.
[3] S. Berger,et al. An NK-like CAR T cell transition in CAR T cell dysfunction , 2021, Cell.
[4] G. Coukos,et al. VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding , 2021, Journal for ImmunoTherapy of Cancer.
[5] R. Jain,et al. Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas , 2021, Nature Communications.
[6] V. Dutoit,et al. Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma , 2021, Frontiers in Immunology.
[7] Christopher A. Miller,et al. Treatment of an Aggressive Orthotopic Murine Glioblastoma Model with Combination Checkpoint Blockade and a Multivalent Neoantigen Vaccine. , 2020, Neuro-oncology.
[8] R. Brentjens,et al. Engineering strategies to overcome the current roadblocks in CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.
[9] D. Irvine,et al. Enhanced CAR–T cell activity against solid tumors by vaccine boosting through the chimeric receptor , 2019, Science.
[10] R. Jain,et al. Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges. , 2019, Annual review of physiology.
[11] Giles W. Robinson,et al. Challenges to curing primary brain tumours , 2019, Nature Reviews Clinical Oncology.
[12] Tracy T Batchelor,et al. Solid stress in brain tumours causes neuronal loss and neurological dysfunction and can be reversed by lithium , 2018, Nature Biomedical Engineering.
[13] R. Martuza,et al. Oncolytic herpes simplex virus immunovirotherapy in combination with immune checkpoint blockade to treat glioblastoma. , 2018, Immunotherapy.
[14] Dai Fukumura,et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges , 2018, Nature Reviews Clinical Oncology.
[15] M. Cilli,et al. Bevacizumab-mediated tumor vasculature remodelling improves tumor infiltration and antitumor efficacy of GD2-CAR T cells in a human neuroblastoma preclinical model , 2018, Oncoimmunology.
[16] R. Martuza,et al. Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade. , 2017, Cancer cell.
[17] Daniel G. Anderson,et al. Ly6Clo monocytes drive immunosuppression and confer resistance to anti-VEGFR2 cancer therapy , 2017, The Journal of clinical investigation.
[18] K. Mansfield,et al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma , 2017, Science Translational Medicine.
[19] Xiuli Wang,et al. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.
[20] Jennie W. Taylor,et al. Abstract LB-347: Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival , 2016 .
[21] R. Jain,et al. Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment. , 2016, Journal of the National Cancer Institute.
[22] Na Li,et al. Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma , 2015, Science Translational Medicine.
[23] R. Jain. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. , 2014, Cancer cell.
[24] R. Jain,et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy , 2012, Proceedings of the National Academy of Sciences.
[25] P. Maffia,et al. A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo. , 2012, Blood.
[26] S. Rosenberg,et al. Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. , 2010, Cancer research.
[27] T. Seyfried,et al. Akt-Dependent Proapoptotic Effects of Dietary Restriction on Late-Stage Management of a Phosphatase and Tensin Homologue/Tuberous Sclerosis Complex 2–Deficient Mouse Astrocytoma , 2008, Clinical Cancer Research.